Antiplatelet drug nonresponsiveness - 08/08/11
Doi : 10.1016/j.ahj.2007.12.034
Patrick Gladding, FCSANZ ⁎ 
, Mark Webster, FCSANZ, John Ormiston, FCSANZ, Sarah Olsen, MBCHB, Harvey White, DSc, FCSANZ
, Mark Webster, FCSANZ, John Ormiston, FCSANZ, Sarah Olsen, MBCHB, Harvey White, DSc, FCSANZ Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
⁎Reprint requests: Patrick Gladding, FCSANZ, Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Auckland Mail Centre, Auckland 1142, New Zealand.
Résumé |
The response to most medication, including antiplatelet drugs, is highly variable between individuals. Observational studies have shown that nonresponders to antiplatelet agents appear to have an increased incidence of vascular events. This review article reviews the background, mechanisms, and evidence in support of the clinial significance of this phenomenon.
Le texte complet de cet article est disponible en PDF.Plan
© 2008
Mosby, Inc. Tous droits réservés.
Vol 155 - N° 4
P. 591-599 - avril 2008 Retour au numéro
Article précédent
- Improving adherence to medications—Can we make this horse drink?
- Debabrata Mukherjee
- A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II—study design and rationale
- Rajendra H. Mehta, John H. Alexander, Robert Emery, Stephen J. Ellis, Vic Hasselblad, Ahmad Khalil, Michel Carrier, Robert A. Harrington, Jean-Claude Tardif, on behalf of the MEND-CABG II Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?